Form 4: Xenon Pharmaceuticals' Chief Medical Officer Granted Stock Options
SEC Form 4 Filing
Christopher Kenney, Chief Medical Officer of Xenon Pharmaceuticals, was granted stock options for 100,000 common shares on March 11, 2024.
Summary
- Christopher Kenney, the Chief Medical Officer of Xenon Pharmaceuticals Inc., was granted stock options on March 11, 2024.
- The stock options grant gives Kenney the right to buy 100,000 common shares at an exercise price of $44.37 per share.
- The options vest 25% on January 1, 2025, and the remaining 75% vest over the following three years in equal monthly installments.
- Kenney also granted a power of attorney to Sherry Aulin, Andrea DiFabio, Ilona Lo, and Nathaniel Adams to handle SEC filings on his behalf.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive.
Positives
- The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize and retain key executives. The size and vesting schedule of the grant are typical for a Chief Medical Officer role.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
- Comparable companies such as BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated also utilize stock options as part of their executive compensation plans.
- The vesting schedule of 25% after one year and the remainder over the following three years is a common vesting structure.
Stakeholder Impact
- The stock option grant aligns the Chief Medical Officer's interests with those of the shareholders, potentially leading to increased focus on long-term value creation.
- Employees may view the grant as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/08/2024 | Date of Power of Attorney execution. |
| 03/11/2024 | Date of the stock option grant. |
| 03/12/2024 | Date of Form 4 filing. |
| 01/01/2025 | First vesting date for 25% of the stock options. |
| 03/10/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.